278
Participants
Start Date
February 1, 2018
Primary Completion Date
September 24, 2019
Study Completion Date
January 9, 2020
CaPre
4 x 1 g capsules administered orally once daily for 26 weeks
Placebo
4 x 1 g capsules administered orally once daily for 26 weeks
Research site, New York
Research site, The Bronx
Research site, Laurelton
Research site, Albany
Research site, New Windsor
Research site, Lansdale
Research site, Manassas
Research site, Aguascalientes
Research site, Hyattsville
Research site, Baltimore
Research site, Morganton
Research site, Gaffney
Research site, Union
Research site, Summerville
Research site, Peachtree Corners
Research site, Dunwoody
Research site, Chihuahua City
Research site, Savannah
Research site, Jacksonville
Research site, Jacksonville
Research site, DeLand
Research site, Miami Lakes
Research site, Miami
Research site, Coral Gables
Research site, Miami
Research site, Miami
Research site, Fort Lauderdale
Research site, Clearwater
Research site, Childersburg
Research site, Birmingham
Research site, Tupelo
Research site, Marion
Research site, Flint
Research site, Iowa City
Research site, Wauconda
Research site, Overland Park
Research site, Norfolk
Research site, Oklahoma City
Research site, Houston
Research site, Houston
Research site, Houston
Research site, Kerrville
Research site, Georgetown
Research site, Monument
Research site, Culiacán
Research site, Boise
Research site, Clinton
Research site, Ogden
Research site, Las Vegas
Research site, Las Vegas
Research site, Torrance
Research site, Long Beach
Research site, Thousand Oaks
Research site, Encino
Research site, San Diego
Research site, Biddeford
Research site, Winnipeg
Research site, Halifax
Research site, Brampton
Research site, Burlington
Research site, London
Research site, Newmarket
Research site, Sarnia
Research site, Québec
Research site, Sherbrooke
Research site, Mexico City
Research site, Mexico City
Research site, Mexico City
Lead Sponsor
Grace Therapeutics Inc.
INDUSTRY